A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Summary

This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.

Timeline

Start

2019-04-15

Primary completion

2024-09-27

Completion

2024-10-08

Drugs

Indications